Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$94.56 USD

94.56
1,346,736

-0.94 (-0.98%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $94.56 0.00 (0.00%) 4:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (142 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Ecolab (ECL) Launches Roach Control Device for Food Outlets

by Zacks Equity Research

Ecolab's (ECL) latest device is expected to help the restaurant industry efficiently protect their brand reputation and eliminate any business and public health risk.

Zacks Equity Research

Here's Why You Should Hold on to Avanos (AVNS) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Avanos (AVNS), owing to its strong product line and focus on its R&D.

Zacks Equity Research

NextGen (NXGN) Implements API to Aid COVID-19 Vaccination

by Zacks Equity Research

NextGen's (NXGN) API is expected to address the unique and evolving reporting needs of various states as they administer the COVID-19 vaccine.

Zacks Equity Research

The Zacks Analyst Blog Highlights: PulteGroup, Weyerhaeuser, General Motors, Illumina and Marriott International

by Zacks Equity Research

The Zacks Analyst Blog Highlights: PulteGroup, Weyerhaeuser, General Motors, Illumina and Marriott International

Nalak Das headshot

Top 5 S&P 500 Stocks at Lucrative Valuation Amid May Turmoil

by Nalak Das

We have narrowed down our search to five S&P 500 stocks that have attained a 52-week high this year but are currently trading at a deep discount. These are: MAR, PHM, WY, GM and ILMN.

Zacks Equity Research

STERIS (STE) Q4 Earnings Fall Shy of Estimates, FY22 View Up

by Zacks Equity Research

STERIS' (STE) fourth-quarter 2021 revenues improved year over year on robust growth across three segments.

Zacks Equity Research

National Vision (EYE) Q1 Earnings Top Estimates, View Up

by Zacks Equity Research

According to National Vision (EYE), increased demand for low-cost eye exams, glasses and contact lenses boosts first-quarter performance.

Zacks Equity Research

Haemonetics (HAE) Q4 Earnings Lag Estimates, Gross Margin Dips

by Zacks Equity Research

Haemonetics' (HAE) fourth-quarter fiscal 2021 revenues declined 5.6% year over year due to the pandemic.

Zacks Equity Research

Here's Why You Should Add Bruker (BRKR) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Bruker (BRKR) on its slew of product launches and potential in the BSI Nano Group.

Zacks Equity Research

Cardiovascular Systems (CSII) Q3 Loss Widens, Gross Margin Dips

by Zacks Equity Research

Increase in vaccinations and simultaneous decrease in COVID-19 hospitalizations in February and March result in improved procedure volumes for Cardiovascular Systems (CSII) in Q3.

Zacks Equity Research

Here's Why You Should Hold on to Illumina (ILMN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and robust adoption of its products.

Zacks Equity Research

Intersect ENT (XENT) Q1 Loss Wider Than Expected, Revenues Top

by Zacks Equity Research

Intersect ENT (XENT) first-quarter revenues improved year over year on increased PROPEL and SINUVA sales.

Zacks Equity Research

Phibro (PAHC) Q3 Earnings Beat Estimates, Margins Decline

by Zacks Equity Research

Phibro's (PAHC) fiscal third-quarter revenues improved year over year on growth in Performance Products and Mineral Nutrition segments.

Zacks Equity Research

Tandem Diabetes (TNDM) Q1 Net Loss Narrows, Guidance Up

by Zacks Equity Research

Tandem Diabetes' (TNDM) strong international and domestic pump sales and shipment boosted the first-quarter top line.

Zacks Equity Research

NuVasive (NUVA) Q1 Earnings Top Estimates, Gross Margin Up

by Zacks Equity Research

NuVasive's (NUVA) first-quarter revenues improved year over year led by progress in U.S. procedural volumes and international business.

Zacks Equity Research

Cerner (CERN) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Cerner's (CERN) first-quarter results benefit from gains in Licensed software, Subscriptions and Managed services units, and expansion in gross margin.

Zacks Equity Research

Exact Sciences (EXAS) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Exact Sciences' (EXAS) first-quarter 2021 revenues improved year over year led by growth in Precision Oncology, COVID-19 testing and Screening revenues.

Zacks Equity Research

PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

PerkinElmer's (PKI) first-quarter results benefit from strong segmental performance.

Zacks Equity Research

Globus Medical (GMED) Q1 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Globus Medical's (GMED) first-quarter 2021 revenues improved year over year on strength in Enabling Technologies and U.S. Spine.

Zacks Equity Research

AmerisourceBergen (ABC) Q2 Earnings Beat, Revenues Miss

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal second-quarter results benefit from segmental growth.

Zacks Equity Research

Zimmer Biomet (ZBH) Q1 Earnings Top, Operating Margin Up

by Zacks Equity Research

Zimmer Biomet's (ZBH) core hip and S.E.T. business registers growth in the reported quarter.

Zacks Equity Research

CVS Health (CVS) Q1 Earnings Beat Estimates, EPS View Up

by Zacks Equity Research

CVS Health's (CVS) revenues across all the three operating segments improve in Q1. Increased guidance amid the pandemic scenario is another positive.

Zacks Equity Research

QIAGEN (QGEN) Q1 Earnings Beat Estimates, 2021 Guidance Up

by Zacks Equity Research

QIAGEN's (QGEN) first-quarter 2021 revenues improved year over year on strong demand for product groups addressing the critical demand for COVID-19 testing.

Zacks Equity Research

Hill-Rom (HRC) Q2 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Hill-Rom's (HRC) second-quarter revenues improved year over year on continued recovery across all three business segments as well as expanded demand for critical care products.

Zacks Equity Research

Illumina (ILMN) Q1 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

Illumina (ILMN) exhibits an impressive performance by its Instruments segment in the first quarter of 2021 despite pandemic-led business disruptions.